| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vivo |
By lengthening contraction time and maintaining actin-myosin separation, Danicamtiv specifically increases cardiac actomyosin activity (the molecular force-generating unit of sarcomeres), enabling relaxing without compromising Ca2+ homeostasis [2].
|
|---|---|
| References |
|
| Molecular Formula |
C16H20F3N5O4S
|
|---|---|
| Molecular Weight |
435.421312332153
|
| Exact Mass |
435.12
|
| Elemental Analysis |
C, 44.14; H, 4.63; F, 13.09; N, 16.08; O, 14.70; S, 7.36
|
| CAS # |
1970972-74-7
|
| PubChem CID |
122424426
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
1.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
701
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@@](C1CCN(CC1)C(=O)NC2=NOC=C2)(F)S(=O)(=O)C3=CN(N=C3C(F)F)C
|
| InChi Key |
NREKKBAMVWQRES-MRXNPFEDSA-N
|
| InChi Code |
InChI=1S/C16H20F3N5O4S/c1-16(19,29(26,27)11-9-23(2)21-13(11)14(17)18)10-3-6-24(7-4-10)15(25)20-12-5-8-28-22-12/h5,8-10,14H,3-4,6-7H2,1-2H3,(H,20,22,25)/t16-/m1/s1
|
| Chemical Name |
4-[(1R)-1-[3-(difluoromethyl)-1-methylpyrazol-4-yl]sulfonyl-1-fluoroethyl]-N-(1,2-oxazol-3-yl)piperidine-1-carboxamide
|
| Synonyms |
Danicamtiv; MYK-491; MYK 491; MYK491;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~114.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2966 mL | 11.4832 mL | 22.9663 mL | |
| 5 mM | 0.4593 mL | 2.2966 mL | 4.5933 mL | |
| 10 mM | 0.2297 mL | 1.1483 mL | 2.2966 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05952089 | Completed | Drug:Danicamtiv Drug:Midazolam |
Heart Failure With Reduced Ejection Fraction |
Bristol-Myers Squibb | August 17, 2023 | Phase 1 |
| NCT05162222 | Completed | Drug:Danicamtiv Drug:Itraconazole Drug:Diltiazem |
Healthy Participants | Bristol-Myers Squibb | December 15, 2021 | Phase 1 |
| NCT04572893 | Terminated | Drug:danicamtiv | Primary Familial Dilated Cardiomyopathy |
Bristol-Myers Squibb | August 4, 2020 | Phase 2 |
| NCT05806359 | Completed | Drug:Danicamtiv Drug:Placebo |
Healthy Volunteers | Bristol-Myers Squibb | March 31, 2023 | Phase 1 |
| NCT03447990 | Completed | Drug:MYK-491 Drug:Placebo |
Heart Failure With Reduced Ejection Fraction |
Bristol-Myers Squibb | February 6, 2018 | Phase 1 Phase 2 |
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
